The short answer
In the STEP-1 extension, participants who stopped semaglutide after 68 weeks regained roughly two-thirds of the weight they had lost within one year, moving from 17.3% mean reduction to a net 5.6%. A 2026 meta-analysis of 37 studies estimated regain at approximately 0.8 kg per month after stopping semaglutide or tirzepatide.
Key facts
- STEP-1 reduction at 68 weeks
- 17.3% mean
- Net reduction one year after stopping
- 5.6%
- Proportion of loss regained
- About two-thirds
- Meta-analysis regain rate
- ~0.8 kg per month
- Meta-regression maximum regain
- 75.3%, half-life ~23 weeks
- Still ≥5% below baseline at 1 year
- Nearly half of participants
What the STEP-1 extension actually found
Participants in the STEP-1 extension had reached 17.3% mean weight reduction at 68 weeks on semaglutide. One year after treatment stopped, they had regained 11.6 percentage points, leaving a net reduction of 5.6% from baseline. That is roughly two-thirds of the loss returning within twelve months of cessation.
The part that gets omitted
Coverage of this finding usually stops at 'two-thirds regained', which is accurate but incomplete. Average weight remained below baseline a year after stopping, and nearly half of participants were still at least 5% below their starting weight. Regain was substantial and partial, not total, and the distribution matters as much as the mean.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the meta-analyses add
A systematic review and nonlinear meta-regression across six randomised controlled trials estimated a maximum regain of 75.3% of lost weight, with a recovery rate constant corresponding to a half-life of about 23 weeks. Separately, a 2026 meta-analysis covering 37 studies and 9,341 people estimated regain of roughly 0.8 kg per month after stopping semaglutide or tirzepatide. The two approaches converge on the same picture: regain is predictable, gradual and incomplete.
Why this is the field's central unresolved question
Every compound in the pipeline reports its headline figure on treatment. None of them has resolved what happens after. This is why maintenance-dosing studies matter more than another few percentage points of peak reduction. TRIUMPH-6, registered as NCT06859268, is retatrutide's maintenance study, and equivalents exist across the class. Until those read out, peak reduction figures describe a state that has to be sustained rather than an outcome that has been achieved.
What it does not tell you
These are trial populations under trial conditions, and cessation in a trial is not the same as cessation in practice. The data describe what happened on average to specific cohorts; they are not a prediction for any individual and are not guidance about starting or stopping anything. That is a decision for a prescriber.
Frequently asked questions
Is all the weight regained?
No. In the STEP-1 extension about two-thirds returned within a year, and average weight remained below baseline, with nearly half of participants still at least 5% down.
How fast does regain happen?
Meta-analysis estimates put it at roughly 0.8 kg per month, with meta-regression suggesting a half-life around 23 weeks toward a maximum of about 75% of the loss.
Do the newer compounds solve this?
Not yet demonstrated. Maintenance studies are running across the class, including TRIUMPH-6 for retatrutide, and none had resolved the question at the time of writing.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- How to Read a Weight-Loss Trial Result ProperlyEstimands, populations, durations and discontinuation rates. Why CagriSema reports both 22.7% and 20.4%, and why headline percentages are not comparable.
- Oral Semaglutide vs OrforglipronBoth are tablets, only one is a peptide. Why oral semaglutide needs SNAC and a fasting window while orforglipron needs neither, and what that costs each.
- What Is Aleniglipron? The Second Oral Small-Molecule GLP-1Aleniglipron is an oral non-peptide GLP-1 agonist from Structure Therapeutics. ACCESS reported 12.1% at 36 weeks; ACCESS II reported 15.3% absolute at 44 weeks.
- What Is Semaglutide? Structure, Mechanism and EvidenceSemaglutide is a GLP-1 analogue with 94% homology to native GLP-1. Its structure, the C18 diacid that gives it a weekly half-life, and the SELECT outcome data.
- What Is Tirzepatide? The First Dual Incretin AgonistTirzepatide is a dual GIP and GLP-1 receptor agonist built on a GIP backbone. SURMOUNT-1 reported up to 22.5% weight reduction over 72 weeks.